In a moment when nations are reckoning with the fragility of global supply chains, the World Bank's private lending arm has chosen to anchor pharmaceutical resilience in Mexican soil. The IFC's financing of Neolpharma's expansion—covering active ingredients and injectable medicines—reflects a growing conviction that access to medicine is too vital to leave entirely to distant markets. Beyond the economics, the deal carries an unusual moral architecture: loan terms that reward the inclusion of people with disabilities in skilled work, a first in the IFC's global history. It is a quiet signal th